共 50 条
- [42] CRISPR/Cas9-targeting of CD40 in hematopoietic stem cells limits immune activation mediated by anti-CD40 PLOS ONE, 2020, 15 (03):
- [50] Phase 1 study to evaluate the safety and tolerability of the CD40 agonistic monoclonal antibody APX005M in subjects with solid tumors JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5